Disapplication of Falsified Medicines Directive Safety Features: Requirements for Parallel Imports

AI Summary

This regulatory guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines a significant policy shift regarding the EU Falsified Medicines Directive (FMD) in Northern Ireland. Effective January 1, 2025, the EU FMD safety features—including unique identifiers and anti-tamper devices—will no longer be a requirement for medicinal products in Northern Ireland. This change follows the implementation of the Windsor Framework, which aims to streamline the movement of medicines between Great Britain and Northern Ireland. The guidance specifically addresses holders of Parallel Import (PLPI) licenses rather than a single specific company. While the mandatory application of EU safety features is being phased out, these companies face critical regulatory obligations to maintain supply chain integrity. The primary concern identified is the potential for products intended for the UK market to inadvertently re-enter the European Union supply chain. Consequently, the MHRA mandates that all PLPI license holders implement robust procedures to decommission medicine packs correctly. Required actions for these stakeholders include ensuring that any packs previously carrying EU FMD features are handled such that they are permanently removed from the EU tracking systems. This is necessary to prevent regulatory violations related to falsified medicines and unauthorized parallel trade. Although specific inspection dates were not detailed in this announcement, the MHRA emphasizes that compliance with these decommissioning standards is mandatory starting in 2025. Failure to adhere to these guidelines could lead to administrative actions or the suspension of import licenses. This shift represents a broader effort to align Northern Ireland’s pharmaceutical regulations with the rest of the United Kingdom while honoring post-Brexit trade agreements.